{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:21:04Z","timestamp":1767453664637,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Aileens Pharma srl"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>(1) Inverse psoriasis (IP), also known as intertriginous, typically affects the groin, armpits, navel, intergluteal fissure, and external genitalia. Skin lesions are erythematous plaques of inflammatory nature, smooth, well-delimited, non-scaly, and non-infiltrated. Lesions may be accompanied by itching, pain, or burning sensation. The aim of this study is both to investigate the modulation of the skin microbiota induced by IP and, on the other hand, to test the effectiveness of the new biotechnological product LimpiAL 2.5%. (2) Patients affected by IP were recruited in a private practice and treated for 4 weeks with LimpiAL 2.5% exclusively. The clinical effects on the lesion skin were evaluated, and the skin microbiotas before and after treatment were compared. (3) The clinical outcomes reveled a significant beneficial effect of the tested product. At the same time, LimpiAL increased the biological diversity of the skin microbiota and exerted a significant decrease of some Corynebacterium species, and the increase of some Staphylococcus species. (4) Together, the clinical outcomes and the microbiota analysis suggest that LimpiAL treatment improves the skin condition of affected patients, basically restoring the eubiosis conditions of the affected sites and modulating the bacterial composition of the resident microbiota.<\/jats:p>","DOI":"10.3390\/ijms24076339","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T02:58:21Z","timestamp":1679972301000},"page":"6339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7636-5581","authenticated-orcid":false,"given":"Laura","family":"Pietrangelo","sequence":"first","affiliation":[{"name":"Dipartimento di Medicina e Scienze della Salute \u201cV. Tiberio\u201d, Universit\u00e0 degli Studi del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9504-5882","authenticated-orcid":false,"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Magnifico","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Scienze della Salute \u201cV. Tiberio\u201d, Universit\u00e0 degli Studi del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5098-7785","authenticated-orcid":false,"given":"Giulio","family":"Petronio Petronio","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Scienze della Salute \u201cV. Tiberio\u201d, Universit\u00e0 degli Studi del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1753-2399","authenticated-orcid":false,"given":"Marco Alfio","family":"Cutuli","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Scienze della Salute \u201cV. Tiberio\u201d, Universit\u00e0 degli Studi del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4952-1889","authenticated-orcid":false,"given":"Noemi","family":"Venditti","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Scienze della Salute \u201cV. Tiberio\u201d, Universit\u00e0 degli Studi del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Guarnieri","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Scienze della Salute \u201cV. Tiberio\u201d, Universit\u00e0 degli Studi del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilian University Munich, 80539 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-4597","authenticated-orcid":false,"given":"Roberto","family":"Di Marco","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Scienze della Salute \u201cV. Tiberio\u201d, Universit\u00e0 degli Studi del Molise, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"ltac016","DOI":"10.1093\/immadv\/ltac016","article-title":"Prevalence of Inverse Psoriasis Subtype with Immune Checkpoint Inhibitors","volume":"2","author":"Jfri","year":"2022","journal-title":"Immunother. Adv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/CCID.S189000","article-title":"Inverse Psoriasis: From Diagnosis to Current Treatment Options","volume":"12","author":"Micali","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_3","first-page":"760","article-title":"Treatment of Inverse\/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation","volume":"16","author":"Khosravi","year":"2017","journal-title":"J. Drugs Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"G\u00f6bl\u00f6s, A., Varga, E., Farkas, K., \u00c1rvai, K., and Kem\u00e9ny, L. (2021). Genetic Investigation of Inverse Psoriasis. Life, 11.","DOI":"10.3390\/life11070654"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11532060-000000000-00000","article-title":"Inverse Psoriasis: Case Presentation and Review","volume":"12","author":"Syed","year":"2011","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clindermatol.2015.04.007","article-title":"Psoriasis Inversa: A Separate Identity or a Variant of Psoriasis Vulgaris?","volume":"33","author":"Omland","year":"2015","journal-title":"Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00105-020-04558-7","article-title":"Intertriginous Psoriasis","volume":"71","author":"Thomas","year":"2020","journal-title":"Hautarzt"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e12589","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and Undertreated Psoriasis: Nuances of Treating Psoriasis Affecting the Scalp, Face, Intertriginous Areas, Genitals, Hands, Feet, and Nails","volume":"31","author":"Merola","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3122\/jabfm.2013.02.120210","article-title":"Resistant \u201cCandidal Intertrigo\u201d: Could Inverse Psoriasis Be the True Culprit?","volume":"26","author":"Wilmer","year":"2013","journal-title":"J. Am. Board Fam. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00105-015-3628-7","article-title":"Psoriasis Inversa","volume":"66","author":"Weisenseel","year":"2015","journal-title":"Hautarzt"},{"key":"ref_11","unstructured":"Chung, J., Strober, B.E., and Weinstock, G.M. (2020). Skin Microbiome Handbook: From Basic Research to Product Development, John Wiley & Sons."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1080\/09546634.2019.1620912","article-title":"Treatments for Inverse Psoriasis: A Systematic Review","volume":"31","author":"Reynolds","year":"2020","journal-title":"J. Dermatolog. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ijd.IJD_169_17","article-title":"Use of Topical Corticosteroids in Dermatology: An Evidence-Based Approach","volume":"62","author":"Das","year":"2017","journal-title":"Indian J. Dermatol."},{"key":"ref_14","first-page":"337","article-title":"Topical Corticosteroids: Choice and Application","volume":"103","author":"Stacey","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dth.12728","article-title":"Update of Calcineurin Inhibitors to Treat Inverse Psoriasis: A Systematic Review","volume":"31","author":"Dattola","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/247553031600200106","article-title":"Inverse Psoriasis: A Review of Topical Therapies","volume":"3","author":"Levy","year":"2016","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Magnifico, I., Petronio, G.P., Venditti, N., Cutuli, M.A., Pietrangelo, L., Vergalito, F., Mangano, K., Zella, D., and Di Marco, R. (2020). Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110411"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112327","DOI":"10.1016\/j.biopha.2021.112327","article-title":"LimpiAD Foam and the Potential Control of the Pressure Ulcers Onset","volume":"144","author":"Pietrangelo","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1111\/jdv.17431","article-title":"HAc40 Is a Novel Microbiome Modulator, Effective on Atopic Dermatitis in Children: Data from Two Pilot Vehicle-Controlled Trials","volume":"35","author":"Sacchetti","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","unstructured":"Rungjang, A., Meephansan, J., and Thio, H.B. (2016). Skin and Gut Microbiota in Psoriasis: A Systematic Review, Intech."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40168-018-0533-1","article-title":"Alteration of the Cutaneous Microbiome in Psoriasis and Potential Role in Th17 Polarization","volume":"6","author":"Chang","year":"2018","journal-title":"Microbiome"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41522-017-0022-5","article-title":"Unexplored Diversity and Strain-Level Structure of the Skin Microbiome Associated with Psoriasis","volume":"3","author":"Tett","year":"2017","journal-title":"NPJ Biofilms Microbiomes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.jid.2018.03.1501","article-title":"Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial","volume":"138","author":"Loesche","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","article-title":"Tralokinumab Treatment Improves the Skin Microbiota by Increasing the Microbial Diversity in Adults with Moderate-to-Severe Atopic Dermatitis: Analysis of Microbial Diversity in ECZTRA 1, a Randomized Controlled Trial","volume":"88","author":"Beck","year":"2022","journal-title":"J. Am. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jaad.2019.06.024","article-title":"Psoriatic Lesions Are Characterized by Higher Bacterial Load and Imbalance between Cutibacterium and Corynebacterium","volume":"82","author":"Quan","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Benhadou, F., Mintoff, D., Schnebert, B., and Thio, H. (2018). Psoriasis and Microbiota: A Systematic Review. Diseases, 6.","DOI":"10.3390\/diseases6020047"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/bjd.17989","article-title":"Combined Culture and Metagenomic Analyses Reveal Significant Shifts in the Composition of the Cutaneous Microbiome in Psoriasis","volume":"181","author":"Langan","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_28","unstructured":"Mokhena, T., Mochane, M., Tshwafo, M., Linganiso, L., Thekisoe, O., and Songca, S. (2016). We Are IntechOpen, the World\u2019 s Leading Publisher of Open Access Books Built by Scientists, for Scientists TOP 1%, Intech."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.4315\/0362-028X.JFP-18-111","article-title":"Purification and Characterization of Pasteuricin Produced by Staphylococcus Pasteuri RSP-1 and Active against Multidrug-Resistant Staphylococcus Aureus","volume":"81","author":"Hong","year":"2018","journal-title":"J. Food Prot."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10068-014-0133-1","article-title":"A New Antimicrobial Substance Produced by Staphylococcus Pasteuri Isolated from Vegetables","volume":"23","author":"Hong","year":"2014","journal-title":"Food Sci. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Newstead, L.L., Varjonen, K., Nuttall, T., and Paterson, G.K. (2020). Staphylococcal-Produced Bacteriocins and Antimicrobial Peptides: Their Potential as Alternative Treatments for Staphylococcus Aureus Infections. Antibiotics, 9.","DOI":"10.3390\/antibiotics9020040"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:04:38Z","timestamp":1760123078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076339"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076339","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}